Transbronchial Lung Cryobiopsy in Undiagnosed Acute Respiratory Failure

Sponsor
China-Japan Friendship Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05754866
Collaborator
(none)
100
6
2
33
16.7
0.5

Study Details

Study Description

Brief Summary

In patients with acute hypoxemic respiratory failure whose diagnosis is not established after initial evaluation, obtaining a histopathological diagnosis may improve the patients' prognosis. In our previous retrospective-controlled study, transbronchial lung cryobiopsy (TBLC) can lead to an increased chance of establishing a diagnosis compared with transbronchial lung biopsy (TBLB), with an acceptable safety profile. Therefore, further prospective randomized controlled studies exploring whether TBLC leads to improved prognosis for such patients are warranted.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Transbronchial lung cryobiopsy
  • Procedure: Transbronchial lung biopsy
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Transbronchial Lung Biopsy Versus Transbronchial Lung Cryobiopsy in Critically Ill Patients With Undiagnosed Acute Hypoxemic Respiratory Failure: a Multicenter Prospective Study
Anticipated Study Start Date :
Mar 1, 2023
Anticipated Primary Completion Date :
Nov 1, 2025
Anticipated Study Completion Date :
Nov 30, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Transbronchial lung cryobiopsy

Procedure: Transbronchial lung cryobiopsy
Lung tissue was obtained by transbronchial lung cryobiopsy for subsequent pathology and clinical diagnosis.

Active Comparator: Transbronchial lung biopsy

Procedure: Transbronchial lung biopsy
Lung tissue was obtained by transbronchial lung biopsy for subsequent pathology and clinical diagnosis.

Outcome Measures

Primary Outcome Measures

  1. Diagnostic yield [7 days after procedure]

    The diagnostic yield of each procedure.

Secondary Outcome Measures

  1. Mortality [28 and 60 days]

    The 28-day and 60-day of patients in each group.

  2. Incidence of procedure related adverse events [3 days after procedure]

    Procedure related death, procedure related hemodynamic and respiratory instability, airway bleeding, pneumothorax and other procedure related adverse events.

  3. Hospital stay [up to 60 days]

    Length of hospital stay including ICU and general ward of respiratory medicine.

  4. Organ support [up to 60 days]

    Length of organ support (days).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Diagnosis of acute hypoxemic respiratory failure

  2. Routine assessments [including bronchoscopy, bronchoalveolar lavage fluid cytology and pathogenic (including pathogenic mNGS) tests, blood tests, etc.] do not clarify the etiology, or there is an unexplained disease process

  3. Imaging shows a multi-lobar segmental distribution of ground glass opacity with or without consolidations

  4. Patients' families agreed to participate in the study and signed an informed consent form

Exclusion Criteria:
  1. Significant hemodynamic instability

  2. Uncorrectable coagulopathy

  3. Severe pulmonary hypertension

  4. Acute coronary syndrome

  5. Intermediate-high-risk acute pulmonary embolism

  6. Acute phase of stroke

  7. Severe emphysema

  8. Aortic dissection and massive gastrointestinal bleeding

  9. Other conditions that are not suitable for participation in the clinical trial

Contacts and Locations

Locations

Site City State Country Postal Code
1 China-Japan Friendship Hospital Beijing China
2 The Second Xiangya Hospital Changsha China
3 The First Affiliated Hospital of Nanchang University Nanchang China
4 The First Affiliated Hospital of Soochow University Suzhou China
5 The Sixth Hospital of Wuhan Wuhan China
6 The First Affiliated Hospital of Zhengzhou University Zhengzhou China

Sponsors and Collaborators

  • China-Japan Friendship Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Shiyao Wang, Attending Physician, China-Japan Friendship Hospital
ClinicalTrials.gov Identifier:
NCT05754866
Other Study ID Numbers:
  • CJFH-2022-KY-194
First Posted:
Mar 6, 2023
Last Update Posted:
Mar 6, 2023
Last Verified:
Mar 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 6, 2023